Centessa Pharmaceuticals (NASDAQ:CNTA) Insider Karen Anderson Sells 120,029 Shares

Centessa Pharmaceuticals PLC Sponsored ADR (NASDAQ:CNTA) insider Karen Anderson sold 120,029 shares of Centessa Pharmaceuticals stock in a transaction that occurred on Friday, March 13th. The shares were sold at an average price of $26.25, for a total transaction of $3,150,761.25. Following the transaction, the insider directly owned 62,085 shares in the company, valued at approximately $1,629,731.25. The trade was a 65.91% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink.

Centessa Pharmaceuticals Stock Down 3.3%

Centessa Pharmaceuticals stock traded down $0.89 during mid-day trading on Friday, reaching $26.33. 1,362,238 shares of the company were exchanged, compared to its average volume of 1,141,428. Centessa Pharmaceuticals PLC Sponsored ADR has a 12-month low of $9.60 and a 12-month high of $30.58. The business has a fifty day moving average of $24.69 and a 200 day moving average of $24.24. The firm has a market cap of $3.85 billion, a P/E ratio of -14.39 and a beta of 1.55. The company has a debt-to-equity ratio of 0.36, a quick ratio of 10.57 and a current ratio of 10.56.

Analyst Upgrades and Downgrades

A number of analysts have recently weighed in on CNTA shares. B. Riley Financial raised their price target on shares of Centessa Pharmaceuticals from $33.00 to $42.00 and gave the company a “buy” rating in a report on Monday, December 1st. Oppenheimer lifted their price target on shares of Centessa Pharmaceuticals from $40.00 to $62.00 and gave the stock an “outperform” rating in a report on Wednesday, December 10th. Guggenheim upped their price target on Centessa Pharmaceuticals from $28.00 to $43.00 and gave the stock a “buy” rating in a research report on Tuesday, November 18th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Centessa Pharmaceuticals in a research note on Wednesday, January 21st. Finally, Truist Financial lifted their price target on Centessa Pharmaceuticals from $33.00 to $38.00 and gave the stock a “buy” rating in a research report on Thursday, January 29th. Two investment analysts have rated the stock with a Strong Buy rating, ten have issued a Buy rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, Centessa Pharmaceuticals presently has a consensus rating of “Buy” and an average target price of $39.80.

Institutional Trading of Centessa Pharmaceuticals

Several large investors have recently made changes to their positions in the company. Avoro Capital Advisors LLC raised its stake in Centessa Pharmaceuticals by 116.2% in the 3rd quarter. Avoro Capital Advisors LLC now owns 10,808,080 shares of the company’s stock valued at $262,096,000 after purchasing an additional 5,808,080 shares during the last quarter. EcoR1 Capital LLC grew its holdings in shares of Centessa Pharmaceuticals by 466.4% during the fourth quarter. EcoR1 Capital LLC now owns 3,115,000 shares of the company’s stock worth $77,906,000 after buying an additional 2,565,000 shares in the last quarter. Braidwell LP acquired a new stake in shares of Centessa Pharmaceuticals in the fourth quarter valued at about $54,730,000. Federated Hermes Inc. purchased a new position in shares of Centessa Pharmaceuticals in the third quarter worth about $42,429,000. Finally, Maverick Capital Ltd. purchased a new position in shares of Centessa Pharmaceuticals in the fourth quarter worth about $41,110,000. 82.01% of the stock is currently owned by hedge funds and other institutional investors.

About Centessa Pharmaceuticals

Centessa Pharmaceuticals plc is a global clinical‐stage biopharmaceutical company focused on the discovery and development of innovative therapies across multiple disease areas. The company operates a modular R&D network, bringing together a portfolio of independent, specialist research entities under a single corporate umbrella. This structure is designed to accelerate decision‐making and resource allocation while leveraging deep scientific expertise in each therapeutic domain.

Centessa’s pipeline spans oncology, immunology, neuroscience, cardiovascular and metabolic diseases, as well as rare genetic disorders.